Skip to content
Home/Companies/MedTech/IGS GeboJagema
IGS GeboJagema

IGS GeboJagema

MedTech·Netherlands·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns IGS GeboJagema?

IGS GeboJagema is currently owned by BC Partners through BC Partners XII (2025 vintage), since 2025.

Hand-verified · updated 2026-07-07

BC Partners
Investor
BC Partners
BC Partners XII · 2025 · Buyout

Key facts

HQNetherlands
SectorMedTech
StatusActive
Websitewww.igsgebojagema.nl

More from BC Partners XII

Other portfolio companies in the same fund.

InfoRLife
Active
PharmaSwitzerland· 2026
Biogaran
Biogaran
Active
PharmaFrance· 2025
Fortidia
Fortidia
Active
LogisticsItaly· 2025

More BC Partners portfolio companies

From the same investor, across funds.

PetLab Co.
PetLab Co.
Active
ConsumerUK· 2025
CeramTec XI
CeramTec XI
Active
MedTechGermany· 2022
Fedrigoni
Fedrigoni
Active
IndustrialsItaly· 2022
Havea
Havea
Active
ConsumerFrance· 2022
Madison Logic
Madison Logic
Active
SaaSUS· 2022
Davies
Davies
Active
Business ServicesUK· 2021

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany
Track IGS GeboJagema

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy IGS GeboJagema?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on IGS GeboJagema.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue